MediBioSense are pleased to announce they are part of a successful consortium in receiving €42 million H2020 EU funding.

By MediBioSenseUncategorised
are pleased to announce they are part of a successful consortium in receiving €42 million H2020 EU funding.
MediBioSense will be providing healthcare wearable technologies as part of the project.
The European research project is to Identify Digital Endpoints to Assess FAtigue, Sleep and acTivities of daily living (acronym: IDEA-FAST) in the following neurodegenerative disorders (NDD): Parkinson’s disease and Huntington’s disease and in the following immune-mediated inflammatory diseases (IMID): Rheumatoid arthritis, systemic lupus erythematosus, primary Sjögren’s syndrome, and inflammatory bowel disease.